As of 2025-09-16, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.08) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.37 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -121.6%.
The range of the Relative Valuation is (0.04) - (0.12) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 2.1x - 6.8x | 4.4x |
| Forward P/E multiples | 2.1x - 6.7x | 4.4x |
| Fair Price | (0.04) - (0.12) | (0.08) |
| Upside | -110.4% - -132.9% | -121.6% |
| Date | P/E |
| 2025-09-09 | -19.95 |
| 2025-09-08 | -19.95 |
| 2025-09-04 | -18.84 |
| 2025-09-03 | -17.73 |
| 2025-08-29 | -20.50 |
| 2025-08-28 | -18.56 |
| 2025-08-27 | -17.73 |
| 2025-08-25 | -19.39 |
| 2025-08-22 | -20.22 |
| 2025-08-21 | -20.22 |
| 2025-08-20 | -19.39 |
| 2025-08-19 | -19.39 |
| 2025-08-18 | -20.50 |
| 2025-08-15 | -19.67 |
| 2025-08-14 | -19.67 |
| 2025-08-13 | -19.67 |
| 2025-08-12 | -20.50 |
| 2025-08-11 | -20.50 |
| 2025-08-07 | -19.95 |
| 2025-08-06 | -19.95 |
| 2025-08-05 | -19.95 |
| 2025-08-01 | -18.56 |
| 2025-07-31 | -18.56 |
| 2025-07-30 | -18.56 |
| 2025-07-29 | -18.56 |
| 2025-07-28 | -20.50 |
| 2025-07-25 | -18.28 |
| 2025-07-24 | -18.84 |
| 2025-07-23 | -19.12 |
| 2025-07-22 | -18.56 |
| 2025-07-21 | -18.56 |
| 2025-07-17 | -17.73 |
| 2025-07-16 | -17.73 |
| 2025-07-15 | -18.84 |
| 2025-07-14 | -19.95 |
| 2025-07-11 | -19.39 |
| 2025-07-09 | -19.12 |
| 2025-07-07 | -18.84 |
| 2025-07-04 | -19.39 |
| 2025-07-03 | -18.28 |
| 2025-07-02 | -16.62 |
| 2025-06-27 | -17.73 |
| 2025-06-26 | -18.28 |
| 2025-06-25 | -18.28 |
| 2025-06-24 | -18.56 |
| 2025-06-23 | -17.73 |
| 2025-06-18 | -17.73 |
| 2025-06-17 | -17.73 |
| 2025-06-16 | -17.73 |